Market Highlights: Gemtuzumab Ozogamicin (GO) is the first Antibody-Drug Conjugate (ADC) approved for acute myeloid leukaemia (AML) induction therapy. When paired with standard cytarabine/anthracycline-based induction chemotherapy in fractionated doses, GO substantially increases the outcome in previously untreated AML patients.. The US Food and Drug Administration (FDA) approved Gemtuzumab Ozogamicin (GO) in 2000 for the treatment of newly diagnosed CD33+ Acute Myeloid Leukaemia in adults and CD33+ Acute Myeloid Leukaemia in children aged 2 years who have had a relapse or who have not responded to initial treatment. The market study is being classified by Type (5mg/Vial and 4.5mg/Vial), by Application (Hospital and Pharmacy) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Key Players: The prominent players in the Gemtuzumab Ozogamicin Drugs are Pfizer (United States).
On 16th June, 2020 - The FDA Expanded the Label of Gemtuzumab Ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) For Newly Diagnosed CD33-Positive Acute Myeloid Leukaemia (AML) To Cover Children Aged One Month and Up.
Key Questions Answered in the Report What will the Gemtuzumab Ozogamicin Drugs Market size and the growth rate be in Future? What are the key factors driving the Gemtuzumab Ozogamicin Drugs Market? What are the key market trends and macro-economic impacting the growth of the Gemtuzumab Ozogamicin Drugs Market? What are the challenges to market growth? Who are the key vendors in the Gemtuzumab Ozogamicin Drugs Market? What are the market opportunities and threats faced by the vendors in the Gemtuzumab Ozogamicin Drugs Market? Trending factors influencing the market shares of the Players. What are the key outcomes of the five forces analysis of the Gemtuzumab Ozogamicin Drugs Market?
Research Methodology: The top-down and bottom-up approaches are used to estimate and validate the size of the Global Gemtuzumab Ozogamicin Drugs market. In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Gemtuzumab Ozogamicin Drugs market. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc. Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, Gemtuzumab Ozogamicin Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others. This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc. Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.